ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag bioethics disease medicine culture ecology

bacteria and DNA molecules on a purple background.
Engineering the Microbiome: CRISPR Leads the Way
Mariella Bodemeier Loayza Careaga, PhD | Mar 15, 2024 | 10+ min read
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
A fruit bat in the hands of a researcher
How an Early Warning Radar Could Prevent Future Pandemics
Amos Zeeberg, Undark | Feb 27, 2023 | 8 min read
Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.
The Proteasome: A Powerful Target for Manipulating Protein Levels
John Hines and Craig M. Crews | May 1, 2017 | 10+ min read
The proteasome’s ability to target and degrade specific proteins is proving useful to researchers studying protein function or developing treatments for diseases.
The Surgisphere Scandal: What Went Wrong?
Catherine Offord | Oct 1, 2020 | 10+ min read
The high-profile retractions of two COVID-19 studies stunned the scientific community earlier this year and prompted calls for reviews of how science is conducted, published, and acted upon. The warning signs had been there all along.
Cloning Capsized?
Ted Agres | Aug 19, 2001 | 10+ min read
Biopharmaceutical researchers fear how pending federal legislation outlawing the cloning of human cells will restrict their abilities to find cures for major degenerative diseases.1,2 Some also see lawmakers impinging on established nonhuman cloning techniques essential for the discovery of new drugs and therapies. The source of all this worry? The US House of Representatives passed July 31 by a wide margin a bill (H.R. 2505) sponsored by Reps. David Weldon (R-Fla.) and Bart Stupak (D-Mich.) th
African Sleeping Sickness: A Recurring Epidemic
Ricki Lewis | May 12, 2002 | 5 min read
African trypanosomiasis is making an unwelcome comeback. But unlike other returning diseases, this one has a drug treatment—eflornithine—that disappeared from the market when it failed to cure cancer. Yet like Viagra's origin from a curious side effect in a clinical trial, so too was eflornithine reborn. "When it was discovered that it removes mustaches in women, it suddenly had a market: western women with mustaches," says Morten Rostrup, president of the international council for M
Ethics and war challenge biologists
Eugene Russo(erusso@the-scientist.com) | Mar 24, 2003 | 4 min read
Despite low turnout, ideals and impassioned discussion dominate AIBS meeting.
Researchers Receiving MacArthur Fellowships Demonstrate 'Capacity To Make A Difference'
Bruce Anderson | Sep 14, 1997 | 6 min read
PRIZE WITH A PRICE: Science historian Peter Galison has taken some ribbing from his family since being named a MacArthur fellow. One could almost pity Peter Galison. A historian of science at Harvard University, Galison is one of seven members of the scientific community among the 23 recipients of this year's John D. and Catherine T. MacArthur Foundation Fellowships. The coveted five-year awards provide unrestricted support plus health insurance to talented individuals, with no reports or proj
In A Darwinian World, What Chance For Design?
Steve Bunk | Apr 12, 1998 | 7 min read
Swiss anthropologist Jeremy Narby counts himself among the relatively thin ranks of scientists willing to publicly announce their conviction that nature is "minded," that an intelligence lies behind the development of life. Such a position is heresy to the prevailing scientific view of naturalism, which holds that nature is self-sufficient and the result of undirected processes. These two differing viewpoints usually are framed in the context of a debate between theology and science--creationis

Run a Search

ADVERTISEMENT